Nuwiq now available for haemophilia A
Nuwiq (human coagulation factor VIII, simoctocog alfa) is now available from Octapharma. It is licensed for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Dose and duration depend on the severity of the factor VIII deficiency, location and extent of the bleeding, and the patient’s clinical condition. Net price: 76p per IU.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20067104
Recommended from Pharmaceutical Press